Phathom Pharmaceuticals【PHAT】銘柄情報

Phathom Pharmaceuticals Inc (PHAT) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

9.965

( 1.48% )

買値

9.96

売値

9.97

出来高

439,953

9.74 日の範囲 10.26

7.61 52 週間の範囲 18.31

時価総額

791.521M

前日終値

9.82

始値

9.85

時刻

9.965

最終取引時間

03:49:05

財務取引量

US$ 4,450,785

VWAP

10.1165

平均取引量 (3 か月)

US$ 1,247,751

発行済株式数

79,430,098

配当利回り

PER

-4.86

1 株当たり利益 (EPS)

-2.09

歳入

204.89M

純利益

-157.3M

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD)... Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.phathompharma.com

本社

Florham Park, United States

設立

2026

Phathom Pharmaceuticals Inc is listed in the Healthcare sector of the ナスダック市場 with ticker PHAT. The last closing price for Phathom Pharmaceuticals was US$9.82. Over the last year, Phathom Pharmaceuticals shares have traded in a share price range of US$ 7.61 to US$ 18.31.

Phathom Pharmaceuticals currently has 79,430,098 shares in issue. The market capitalisation of Phathom Pharmaceuticals is US$791.52 million. Phathom Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.86.

Form 4 - Statement of changes in beneficial ownership of securities

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28...

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~1.35 million total VOQUEZNA® prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase...

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.335	3.47871235722	9.63	10.72	9.49	1150233	10.00788871	CS
4	-2.615	-20.786963434	12.58	13.39	8.78	1220302	10.73651247	CS
12	-0.645	-6.07917059378	10.61	13.665	8.78	1237711	11.44296947	CS
26	-4.235	-29.823943662	14.2	18.31	8.78	1177142	12.65504506	CS
52	1.135	12.8539071348	8.83	18.31	7.61	1200906	11.95523289	CS
156	-3.355	-25.1876876877	13.32	19.675	2.21	1063327	10.22614333	CS
260	-24.655	-71.2160600809	34.62	37.17	2.21	729215	10.56761119	CS